Topics

New Head-to-Head Data Show Taltz Superiority vs. Tremfya in Patients with Moderate to Severe Plaque Psoriasis

10:23 EDT 11 Oct 2019 | Speciality Pharma Journal

TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) — Eli Lilly and Company presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. …

Original Article: New Head-to-Head Data Show Taltz Superiority vs. Tremfya in Patients with Moderate to Severe Plaque Psoriasis

NEXT ARTICLE

More From BioPortfolio on "New Head-to-Head Data Show Taltz Superiority vs. Tremfya in Patients with Moderate to Severe Plaque Psoriasis"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...